Eledoisin (CAS 69-25-0) is a high-purity peptide API, isolated from the salivary glands of the octopus Eledone moschata. It acts as a selective vasoactive intestinal peptide (VIP) receptor agonist, exerting a wide range of physiological effects by binding to and activating VIP receptors on target cells.
Produced under strict GMP standards, this API ensures consistent purity (≥98%) and biological activity, making it ideal for pharmaceutical formulation and research. It is widely applied in the development of drugs for the treatment of cardiovascular diseases, such as hypertension and myocardial ischemia, as well as for the management of gastrointestinal disorders and respiratory diseases. It is also a valuable tool in pharmacology and neuroscience research.
Its unique ability to regulate multiple physiological systems makes it a subject of extensive research in drug discovery and development. Eledoisin provides reliable biological activity with a favorable safety profile, catering to the needs of pharmaceutical manufacturers and research institutions in the fields of cardiology, gastroenterology, and neuroscience.
